The influence of circulating anti-Müllerian hormone on ovarian responsiveness to ovulation induction with gonadotrophins in women with polycystic ovarian syndrome: a pilot study

Reproductive Biology and Endocrinology

Robert W Shaw²  Moustafa K Eissa¹  Ahmad R El-Adawy¹  Ayman Abdelmaged¹  Ahmad Mahran¹  Saad A Amer² 

[1] Faculty of Medicine, Minia University, Minia, Egypt;Department of Obstetrics and Gynaecology, Division of Medical Sciences and Graduate Entry Medicine, University of Nottingham, Royal Derby Hospital, Derby DE22 3DT, UK

关键词: Polycystic ovarian syndrome;    Ovulation induction;    Follicle stimulating hormone;    Anti-Müllerian hormone;   

Others  :  809781
DOI  :  10.1186/1477-7827-11-115

 received in 2013-09-23, accepted in 2013-12-02,  发布年份 2013

【 摘 要 】

Background

Women with polycystic ovarian syndrome (PCOS) are known to have elevated circulating Anti-Müllerian hormone (AMH), which has been found to desensitize ovarian follicles to follicle stimulating hormone (FSH). The purpose of this study was to investigate the impact of high circulating AMH on ovarian responsiveness to ovulation induction with gonadotrophins in PCOS women.

Methods

This prospective observational pilot study was conducted in two collaborating Fertility Centres in the UK and Egypt. The study included 20 consecutive anovulatory women with PCOS who underwent 34 cycles of human menopausal gonadotrophin (hMG) ovarian stimulation using chronic low-dose step up protocol. Blood samples were collected for the measurement of serum AMH concentrations in the early follicular (day 2-3) phase in all cycles of hMG treatment. The serum levels of AMH were compared between cycles with good vs. poor response. The good response rates and the total dose and duration of hMG treatment were compared between cycles with high vs. low serum AMH concentrations.

Results

Cycles with poor response (no or delayed ovulation requiring >20 days of hMG treatment) had significantly (p = .007) higher median{range} serum AMH concentration (6.5{3.2-13.4}ng/ml) compared to that (4.0{2.2-10.2}ng/ml) of cycles with good response (ovulation within 20 days of hMG treatment). ROC curve showed AMH to be a useful predictor of poor response to hMG stimulation (AUC, 0.772; P = 0.007). Using a cut-off level of 4.7 ng/ml, AMH had a sensitivity of 100% and specificity of 58% in predicting poor response. The good response rate was significantly (p < .001) greater in cycles with lower AMH (<4.7 ng/ml) compared to that in those with AMH > = 4.7 ng/ml (100% vs. 35%, respectively). All cycles with markedly raised serum AMH levels (> 10.2 ng/ml) were associated with poor response. Cycles with high AMH (> = 4.7 ng/ml) required significantly (p < .001) greater amounts (median {range}, 1087{450-1650}IU) and longer duration (20 {12-30}days) of hMG stimulation than cycles with lower AMH (525 {225-900}IU and 8{6-14}days).

Conclusions

PCOS women with markedly raised circulating AMH seem to be resistant to hMG ovulation induction and may require a higher starting dose.

【 授权许可】

   
2013 Amer et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Weenen C, Laven JS, von Bergh AR, Cranfield R, Groome NP, Visser JA, Kramer P, Fauser BCJM, Themmen APN: Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mole Hum Reprod 2004, 10:77-83.
• [2]Durlinger AL, Gruijeters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA, et al.: Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001, 142:4891-4899.
• [3]Pellatt L, Rice S, Dilaver N, Heshri A, Galea R, Brincat M, Brown K, Simpson ER, Mason HD: Anti-Müllerian hormone reduces follicle sensitivity to follicle-stimulating hormone in human granulosa cells. Fertil Steril 2011, 96:1246-1251.
• [4]Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, Dewailly D: Elevated serum level of anti-Müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003, 88:5957-5962.
• [5]Laven JS, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BC: Anti-Mülllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004, 89:318-323.
• [6]Grossman MP, Nakajima ST, Fallat ME, Siow Y: Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 2008, 89(Suppl 5):1364-1370.
• [7]Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM: Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002, 77:468-471.
• [8]van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, Themmen APN: Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve. Hum Reprod 2002, 17:3065-3071.
• [9]Lie Fong S, Schipper I, de Jong F, Themmen APN, Visser JA, Laven JSE: Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil Steril 2011, 96:459-463.
• [10]Xi W, Gong F, Lu G: Correlation of serum Anti-Müllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle with assisted reproduction outcome in polycystic ovary syndrome patients. J Assist Reprod Genet 2012, 29:397-402.
• [11]Hattori Y, Sato T, Okada H, Saito C, Sugiura-Ogasawara M: Comparison of follicular fluid and serum anti-Mullerian hormone levels as predictors of the outcome of assisted reproductive treatment. EUR J Obstet Gynecol Reprod Biol 2013, 169:252-256.
• [12]Hossein G, Arabzadeh S, Hossein-Rashidi B, Hosseini MA: Relations between steroids and AMH: Impact of basal and intrafollicular steroids to AMH ratios on oocyte yield and maturation rate in women with or without polycystic ovary undergoing in vitro fertilization. Gynecol Endocrinol 2012, 28:413-417.
• [13]Parco S, Novelli C, Vascotto F, Princi T: Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome. Int J General Med 2011, 4:759-763.
• [14]Guzman L, Ortega-Hrepich C, Polyzos NP, Anckaert E, Verheyen G, Coucke W, Devroey P, Tournaye H, Smitz J, De Vos M: A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mu¨ llerian hormone and antral follicle count. Hum Reprod 2013, 28:1261-1266.
• [15]Amer S, Li TC, Ledger WL: The value of measuring anti-Müllerian hormone in women with anovulatory polycystic ovary syndrome undergoing laparoscopic ovarian diathermy. Hum Reprod 2009, 24:2760-2766.
• [16]Mahran A, Abdelmeged A, El-Adawy AR, Eissa MK, Shaw RW, Amer SA: The predictive value of circulating anti-Müllerian hormone in women with polycystic ovarian syndrome receiving clomiphene citrate: a prospective observational study. J Clin Endocrinol Metab 2013. in press
• [17]The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19:41-47.
• [18]WHO: Laboratory manual for the examination of human semen and semen–cervical mucus interaction. 4th edition. Cambridge, UK: Cambridge University Press; 1999.